LifeArc plays key role in discovery of new Alzheimer’s treatment
LifeArc played an important part in the discovery of lecanemab, an experimental drug that has shown some benefits for people with early Alzheimer’s disease.
LifeArc’s Head of Ventures, Clare Terlouw speaks with @FT Global Pharma Correspondent @hannahkuchler discussing RQ… https://t.co/fqrxEXr3Xf
LifeArc funds home monitoring trials for people with chronic respiratory conditions
Trials will examine the impact of home monitoring and machine learning decision support algorithms for people with CF and bronchiectasis.
LifeArc Ventures invests in Surgery Hero, world’s first digital coaching clinic for patients
Seed funding will be used to scale the solution through the application of machine learning
Call for Government to place medical research at the heart of economic plans
Ahead of the Autumn Statement, LifeArc and other leading life science organisations have written to the Chancellor…
LifeArc contributes to organic chemistry breakthrough
The findings reveal that seemingly impossible chemical reactions can be driven through a phenomenon called quantum tunnelling.
AbbVie acquires LifeArc portfolio company DJS Antibodies
AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS
LifeArc’s new fund to advance gene-based medicines for genetic diseases
Researchers can now apply for funding to progress exciting gene therapy research.
New toolkit launched to help repurposed medicines reach patients
The toolkit helps researchers, charities and others navigate the opportunities and challenges of repurposing medicines.
LifeArc scientist awarded prestigious industrial fellowship
LifeArc scientist Finbar Gaffey awarded a coveted industrial fellowship from the Royal Commission for the Exhibition of 1851.